AOCI at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's AOCI?
- BioCryst Pharmaceuticals (BCRX) reported AOCI of -$368K in Q1 2026.
- How has BioCryst Pharmaceuticals's AOCI changed year-over-year?
- BioCryst Pharmaceuticals's AOCI decreased by 132.5% year-over-year, from $1.13M to -$368K.
- What is the long-term trend for BioCryst Pharmaceuticals's AOCI?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's AOCI has grown at a 66.2% compound annual growth rate (CAGR), from $3K to $38K.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.